Clinical Trial Update: Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a more frequent Lucentis dosing regimen for persistent diabetic macular edema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Maturi, Raj K., M.D., P.C. | Conditions: Persistent Diabetic Macular Edema | Phase 2 | Status: WITHDRAWN